Additional Infant Patient to Receive Jaguar Health's Crofelemer for ...
(PR-inside.com) Jaguar remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support (PS) for pediatric and adult rare IF diseases, including microvillus inclusion disease (MVID) Company plans to file NDA for crofelemer for MVID in mid-2027 to obtain F…
Short extract only — this publisher licenses its text. Read the full release at the source.
Free plan · Plus CA$29 or Pro CA$99/month


